DDInter542 DDInter1652
Dicoumarol is an oral anticoagulant agent that works by interfering with the metabolism of vitamin K. In addition to its clinical use, it is also used in biochemical experiments as an inhibitor of reductases.
Secukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque psoriasis. By blocking the actions of IL-17A, secukinumab works to inhibit the pro-inflammatory pathways that drive immune-mediated inflammatory disorders. Following its first global approval in Japan in December 2014, secukinumab was approved by the European Commission on January 15, 2015, and by the FDA a few days after (January 21, 2015). It is currently approved to treat a number of chronic inflammatory conditions, such as plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa.[L39600,L42280,L48771]
Dicoumarol {u} (Compound) resembles {v} (Compound) Phenprocoumon
Dicoumarol {u} (Compound) binds {v} (Gene) CYP2C9
Dicoumarol {u} (Compound) downregulates {v} (Gene) P4HTM
Dicoumarol (Compound) resembles Phenprocoumon (Compound)
Dicoumarol (Compound) binds CYP2C9 (Gene)
Dicoumarol (Compound) downregulates P4HTM (Gene)